Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Cash: 2014-2024

Historic Change in Cash for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to -$89.5 million.

  • Protagonist Therapeutics' Change in Cash rose 75.58% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 82.55%. This contributed to the annual value of -$89.5 million for FY2024, which is 246.73% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Change in Cash stood at -$89.5 million for FY2024, which was down 246.73% from $61.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Change in Cash registered a high of $84.4 million during FY2020, and its lowest value of -$89.5 million during FY2024.
  • Moreover, its 3-year median value for Change in Cash was $2.1 million (2022), whereas its average is -$8.8 million.
  • In the last 5 years, Protagonist Therapeutics' Change in Cash spiked by 2,833.29% in 2023 and then plummeted by 246.73% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Change in Cash (Yearly) stood at $84.4 million in 2020, then slumped by 92.80% to $6.1 million in 2021, then plummeted by 65.76% to $2.1 million in 2022, then spiked by 2,833.29% to $61.0 million in 2023, then plummeted by 246.73% to -$89.5 million in 2024.